A few selected segments from a 6-minute animation created for a first-in-class B-cell maturation antigen (BCMA)-directed personalized immunotherapy called chimeric antigen receptor (CAR) T-cell therapy.
In this CAR T therapy, the T cells are engineered to target a protein called BCMA, which is found in abundance on multiple myeloma cells, but is absent from nearly all normal cells.
